© 2020 Marker Therapeutics, Inc.
Houston, TX – September 17, 2020– Marker Therapeutics, Inc. (NASDAQ:MRKR),
a clinical-stage immuno-oncology company specializing
in the development of next-generation T cell-based immunotherapies for the
treatment of hematological malignancies and solid tumor indications, today
announced that its President and Chief Executive Officer, Peter L. Hoang, will
present at the upcoming Virtual Oppenheimer Fall Healthcare Life Sciences &…
Marker Therapeutics, Inc., today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.
Marker Therapeutics, Inc., today announced that it has executed a lease agreement to establish a cGMP manufacturing facility in Houston, TX, in an area near the George Bush Intercontinental Airport. The facility will allow production according to U.S. Food and Drug Administration (FDA) guidelines and is designed to be scalable using modular processes. The facility is expected to be completed by year-end and operational in 2021.
Marker Therapeutics, Inc. announced today that the United States Adopted Name (USAN) Council has approved “zelenoleucel” as the nonproprietary (generic) name for MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of patients with acute myeloid leukemia (AML) following allogeneic stem cell transplant in both adjuvant and active disease settings.
Marker Therapeutics, Inc. today announced updated clinical results from an ongoing investigator-sponsored Phase 1 trial led by the Baylor College of Medicine, evaluating the Company’s MultiTAA-specific T cell therapy in patients with advanced or metastatic pancreatic adenocarcinoma. Data from a cohort of patients receiving MultiTAA-specific T cell therapy in combination with standard-of-care chemotherapy in the first-line setting (Arm A), were reviewed today by lead investigator, Brandon G. Smaglo, M.D., FACP, as part of a poster session during the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting. ASCO is being held from Friday, May 29 through Sunday, May 31, 2020.
Marker Therapeutics, Inc. today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for presentation during a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.
Marker Therapeutics, Inc. today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.
Marker Therapeutics today announced that it will host a conference call and webcast on Monday, May 11, 2020 at 5:00 p.m. Eastern Time to review its first quarter 2020 financial and operating results and provide a corporate update.
Marker Therapeutics today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug designation to MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for the treatment of patients with acute myeloid leukemia (AML), following allogeneic stem cell transplant.
Marker Therapeutics today provided a corporate update and reported financial results for the full year ended December 31, 2019.